SHORT ANSWER
Because the category is restricted before your account has a history. Stripe prohibits “incorrectly labeled research chemicals” and WooPayments names “peptides and other research chemicals” outright, citing card-network and banking-partner rules. Those rules turn on legal and reputational exposure, not dispute rates. A clean chargeback record is welcome, but it does not move a product out of a restricted category.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / WHAT THE POLICIES SAY
The restriction is written down, by category
Stripe's restricted businesses page, read September 3, 2026, does not use the word “peptide.” It lists, under prohibited businesses, “incorrectly labeled research chemicals” and “pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims.” Under restricted businesses it lists “card-not-present prescription-only products and pharmaceuticals.”
WooPayments, which runs on Stripe, is more direct. Its prohibited and restricted products page, read the same day, lists “peptides and other research chemicals” by name, beside “supplements supported by unsubstantiated claims” and “pseudo-pharmaceuticals.” It points to Stripe's list as the full set.
Neither page conditions the entry on a merchant's dispute history. The category is the trigger.
Both pages are private policy, not law. They are quoted as read on the date above and may be revised. Check the live page before relying on any line here.
02 / CATEGORY BEFORE HISTORY
The decision is made at onboarding, not after a dispute
Stripe explains the restriction list in one sentence: as a financial services company it must follow financial laws and regulations “as well as rules and policies set by our financial partners, such as card networks and banking partners.” WooPayments says the same thing in its own words, attributing its list to “restrictions put in place by card networks, our payment processors, and their financial service providers.”
That chain matters. A processor's underwriter reads the storefront against those rules when the account is opened, and can read it again at any time. A merchant who has never had a chargeback is evaluated on what the products are and how they are presented, because that is what the rules describe.
03 / HOW A NETWORK REASONS
A clean record does not establish legitimacy
Visa's Online Pharmacy Guide for Acquirers (June 2016) is written for banks that board internet pharmacies, not peptide sellers, but it shows how a card network thinks about healthcare products sold card-not-present. It warns acquirers that risk staff “may be used to viewing risk chiefly from the perspective of fraud, chargebacks, or intellectual property violations,” and then states that for these merchants “the absence of an intellectual property violation or chargeback does not establish its legitimacy.”
The same guide describes a High Brand-Risk Acquirer license that an acquirer must hold before boarding a card-not-present pharmacy merchant, a fine of US $25,000 per month for an acquirer that boards such merchants without registering, and escalating measures up to loss of Visa acceptance. The exposure sits with the acquirer, which is why the acquirer's rules reach the merchant as a category restriction.
Visa's guide addresses prescription medicines. It is cited for its reasoning about healthcare-product merchants, not as a statement that any specific rule applies to a research-peptide storefront.
04 / WHERE CHARGEBACKS STILL MATTER
Disputes are the second gate, not the first
None of this makes chargebacks irrelevant. Once an account exists, dispute rates feed network monitoring programs, reserve decisions, and continued-service reviews. A merchant in a restricted category who also carries a high dispute rate has two problems.
The order is what trips people up. Category review comes first and does not wait for data. Dispute review comes second and uses data. Fixing the second does not answer the first.
05 / THE REGULATORY LAYER
Why “incorrectly labeled” is the phrase to notice
Stripe's wording is “incorrectly labeled research chemicals.” Labeling is the question FDA asks when it decides whether a product is a drug: under 21 CFR § 201.128, intended use is read from labeling, advertising, written statements, and the circumstances of distribution, not from a disclaimer alone. A storefront whose copy describes effects in people, names an approved brand, or bundles injection supplies is presenting the product in a way both a regulator and an underwriter can read as human use.
The companion phrase, products that “make harmful claims,” tracks the FTC's advertising lens. The guide on research-use-only disclaimers walks through both.
06 / WHAT THIS MEANS FOR YOUR STOREFRONT
Expect a category review, and prepare for one
Because the first review is about what you sell and how you present it, the useful preparation is on the storefront, not in the dispute dashboard.
- Read your product names, descriptions, imagery, and bundles the way an underwriter reads them against the quoted policy lines
- Remove or reword anything that describes effects in people or compares a product to an approved drug
- Keep boundary language accurate, and keep it consistent with the rest of the page
- Record what was examined and what was changed, so a provider can see the review rather than take your word for it
- Treat any approval as the provider's decision on its own terms, subject to re-review
QUESTIONS
Related questions
If I switch processors, does the category restriction go away?
Not by itself. Processors that run on Stripe inherit Stripe's list, and other acquirers answer to the same card-network rules. A different provider may weigh the category differently, but the category travels with the products.
Will a low chargeback rate help my application?
It helps once an account exists and is being reviewed for continued service. It does not answer the category question an underwriter asks first, which is about what the products are and how the storefront presents them.
Can RUO Clear get my products out of the restricted category?
No. RUO Clear reports what was observed on the storefront and which policy or source each finding maps to, and helps you fix what is flagged. Whether a provider opens or keeps an account is the provider's decision.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
Lists “incorrectly labeled research chemicals” and unsafe pseudo-pharmaceuticals as prohibited; card-not-present pharmaceuticals as restricted. Read September 3, 2026.
Names “peptides and other research chemicals” and attributes the list to card-network and processor rules. Read September 3, 2026.
Explains why a card network treats card-not-present healthcare merchants as high brand-risk, and states that no chargebacks does not establish legitimacy.
Intended use is read from labeling, advertising, written statements, and circumstances of distribution.